Phathom Pharmaceuticals

OverviewSuggest Edit

Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases and disorders. The company offers Vonoprazan, a small molecule potassium-competitive acid blocker to treat gastroesophageal reflux disease, including erosive esophagitis, gastric and duodenal ulcer, and low dose aspirin-associated ulcer.
TypePublic
Founded2018
HQBuffalo Grove, IL, US
Websitephathompharma.com

Latest Updates

Employees (est.) (Sept 2019)16(+34%)
Share Price (Jan 2021)$38.3 (+6%)
Cybersecurity ratingAMore

Key People/Management at Phathom Pharmaceuticals

Terrie Curran

Terrie Curran

President, Chief Executive Officer & Director
Azmi Nabulsi

Azmi Nabulsi

Chief Operating Officer
James Topper

James Topper

Director
Joe Hand

Joe Hand

Chief Administrative Officer
Todd Branning

Todd Branning

Chief Financial Officer
Michael Cola

Michael Cola

Director
Show more

Phathom Pharmaceuticals Office Locations

Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park
Buffalo Grove, IL, US (HQ)
2150 E Lake Cook Rd #800Buffalo
Florham Park, NJ, US
100 Campus Dr #102
Menlo Park, CA, US
70 Willow Rd
Show all (3)

Phathom Pharmaceuticals Financials and Metrics

Phathom Pharmaceuticals Revenue

USD

Net income (Q2, 2020)

(21.1m)

EBIT (Q2, 2020)

(20.0m)

Market capitalization (14-Jan-2021)

1.1b

Closing stock price (14-Jan-2021)

38.3

Cash (30-Jun-2020)

247.3m

EV

876.3m
Phathom Pharmaceuticals's current market capitalization is $1.1 b.
Annual
USDFY, 2018FY, 2019

General and administrative expense

1.2m6.9m

R&D expense

20.0k20.4m

Operating expense total

2.5m27.3m

EBIT

(1.2m)(106.2m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.8m4.5m5.2m

R&D expense

4.5m15.9m14.9m

Operating expense total

6.3m20.4m20.0m

Depreciation and amortization

77.0k
Annual
USDFY, 2018FY, 2019

Cash

879.0k243.8m

Prepaid Expenses

11.8m

Current Assets

902.0k255.6m

PP&E

463.0k
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

82.9m74.5m256.7m247.3m

Prepaid Expenses

3.2m5.2m1.4m

Current Assets

84.5m77.7m261.8m248.7m

PP&E

40.0k768.0k748.0k
Annual
USDFY, 2018FY, 2019

Net Income

(1.3m)(255.1m)

Depreciation and Amortization

8.0k

Accounts Payable

2.3m

Cash From Operating Activities

(1.0m)(36.5m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(514.0k)(89.0m)(157.1m)(20.1m)(41.2m)

Depreciation and Amortization

2.0k52.0k129.0k

Accounts Payable

1.6m1.5m8.1m

Cash From Operating Activities

(452.0k)(6.0m)(13.1m)(11.4m)(20.8m)
Show all financial metrics

Phathom Pharmaceuticals Operating Metrics

Oct, 2019

Drugs in Development

1

Phase III Trials Products

1
Show all operating metrics

Phathom Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Phathom Pharmaceuticals Online and Social Media Presence

Embed Graph

Phathom Pharmaceuticals News and Updates

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offer…

Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)

Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM…

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

Topline results expected in second half of 2021 Topline results expected in second half of 2021

Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will par…

Phathom Pharmaceuticals to Host Virtual Investor Day

FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today confirmed it will host a virtual Investor Day on Dece…

Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will pa…
Show more

Phathom Pharmaceuticals Frequently Asked Questions

  • When was Phathom Pharmaceuticals founded?

    Phathom Pharmaceuticals was founded in 2018.

  • Who are Phathom Pharmaceuticals key executives?

    Phathom Pharmaceuticals's key executives are Terrie Curran, Azmi Nabulsi and James Topper.

  • How many employees does Phathom Pharmaceuticals have?

    Phathom Pharmaceuticals has 16 employees.

  • Who are Phathom Pharmaceuticals competitors?

    Competitors of Phathom Pharmaceuticals include UNITY Biotechnology, Synthorx and Innovation Pharmaceuticals.

  • Where is Phathom Pharmaceuticals headquarters?

    Phathom Pharmaceuticals headquarters is located at 2150 E Lake Cook Rd #800Buffalo, Buffalo Grove.

  • Where are Phathom Pharmaceuticals offices?

    Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park.

  • How many offices does Phathom Pharmaceuticals have?

    Phathom Pharmaceuticals has 3 offices.